ContraFect Corporation Announces Issuance of Patent for Novel Approach to Treat Influenza Using Inhaled Antibodies
YONKERS, NY--(Marketwired - August 03, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today …